Send to

Choose Destination
J Virol. 2017 Sep 12;91(19). pii: e00401-17. doi: 10.1128/JVI.00401-17. Print 2017 Oct 1.

Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.

Author information

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
Biomedical Primate Research Centre, Rijswijk, The Netherlands.
Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Novartis Vaccines and Diagnostics, Inc., Cambridge, Massachusetts, USA.
Commissariat à l'Energie Atomique, iBiTecS, Service d'Ingénierie Moléculaire des Protéines, Gif-sur-Yvette, France.
Protein Sciences Corporation, Meriden, Connecticut, USA.
Lab of Viral Zoonotics, Cambridge University, Cambridge, England.
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.


Evaluation of the epitope specificities, locations (systemic or mucosal), and effector functions of antibodies elicited by novel HIV-1 immunogens engineered to improve exposure of specific epitopes is critical for HIV-1 vaccine development. Utilizing an array of humoral assays, we evaluated the magnitudes, epitope specificities, avidities, and functions of systemic and mucosal immune responses elicited by a vaccine regimen containing Env cross-linked to a CD4-mimetic miniprotein (gp140-M64U1) in rhesus macaques. Cross-linking of gp140 Env to M64U1 resulted in earlier increases of both the magnitude and avidity of the IgG binding response than those with Env protein alone. Notably, IgG binding responses at an early time point correlated with antibody-dependent cellular cytotoxicity (ADCC) function at the peak immunity time point, which was higher for the cross-linked Env group than for the Env group. In addition, the cross-linked Env group developed higher IgG responses against a linear epitope in the gp120 C1 region of the HIV-1 envelope glycoprotein. These data demonstrate that structural modification of the HIV-1 envelope immunogen by cross-linking of gp140 with the CD4-mimetic M64U1 elicited an earlier increase of binding antibody responses and altered the specificity of the IgG responses, correlating with the rise of subsequent antibody-mediated antiviral functions.IMPORTANCE The development of an efficacious HIV-1 vaccine remains a global priority to prevent new cases of HIV-1 infection. Of the six HIV-1 efficacy trials to date, only one has demonstrated partial efficacy, and immune correlate analysis of that trial revealed a role for binding antibodies and antibody Fc-mediated effector functions. New HIV-1 envelope immunogens are being engineered to selectively expose the most vulnerable and conserved sites on the HIV-1 envelope, with the goal of eliciting antiviral antibodies. Evaluation of the humoral responses elicited by these novel immunogen designs in nonhuman primates is critical for understanding how to improve upon immunogen design to inform further testing in human clinical trials. Our results demonstrate that structural modifications of Env that aim to mimic the CD4-bound conformation can result in earlier antibody elicitation, altered epitope specificity, and increased antiviral function postimmunization.


CD4 mimetic; antibody; epitope exposure; human immunodeficiency virus; nonhuman primate; structural modification; vaccine

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center